[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PL2451945T3 - Wirusy onkolityczne i sposoby leczenia zaburzeń nowotworowych - Google Patents

Wirusy onkolityczne i sposoby leczenia zaburzeń nowotworowych

Info

Publication number
PL2451945T3
PL2451945T3 PL10796626T PL10796626T PL2451945T3 PL 2451945 T3 PL2451945 T3 PL 2451945T3 PL 10796626 T PL10796626 T PL 10796626T PL 10796626 T PL10796626 T PL 10796626T PL 2451945 T3 PL2451945 T3 PL 2451945T3
Authority
PL
Poland
Prior art keywords
methods
oncolytic viruses
neoplastic disorders
treating neoplastic
treating
Prior art date
Application number
PL10796626T
Other languages
English (en)
Inventor
David H. Evans
Don B. Gammon
Original Assignee
The Governors Of The University Of Alberta
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Governors Of The University Of Alberta filed Critical The Governors Of The University Of Alberta
Publication of PL2451945T3 publication Critical patent/PL2451945T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/17Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/76Viruses; Subviral particles; Bacteriophages
    • A61K35/768Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/24011Poxviridae
    • C12N2710/24111Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24121Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/24011Poxviridae
    • C12N2710/24111Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24132Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/24011Poxviridae
    • C12N2710/24111Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24161Methods of inactivation or attenuation
    • C12N2710/24162Methods of inactivation or attenuation by genetic engineering

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL10796626T 2009-07-10 2010-07-09 Wirusy onkolityczne i sposoby leczenia zaburzeń nowotworowych PL2451945T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22469409P 2009-07-10 2009-07-10
CA2709292A CA2709292A1 (en) 2009-07-10 2010-07-08 Oncolytic viruses and methods for treating neoplastic disorders

Publications (1)

Publication Number Publication Date
PL2451945T3 true PL2451945T3 (pl) 2017-09-29

Family

ID=43448742

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10796626T PL2451945T3 (pl) 2009-07-10 2010-07-09 Wirusy onkolityczne i sposoby leczenia zaburzeń nowotworowych

Country Status (8)

Country Link
US (2) US8679509B2 (pl)
EP (1) EP2451945B1 (pl)
CA (2) CA2709292A1 (pl)
DK (1) DK2451945T3 (pl)
ES (1) ES2626657T3 (pl)
PL (1) PL2451945T3 (pl)
PT (1) PT2451945T (pl)
WO (1) WO2011003194A1 (pl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2212345T3 (pl) * 2007-11-19 2016-07-29 Transgene Sa Onkolityczne wektory pokswirusowe
CN102313803A (zh) * 2011-06-21 2012-01-11 贵州大学 山羊痘正向间接血凝诊断试剂及其制备方法和检测方法
KR101632897B1 (ko) * 2013-04-10 2016-06-23 신라젠(주) 백시니아 바이러스로부터 유래한 신규한 항암 바이러스 hbb301
JP6657115B2 (ja) * 2014-04-10 2020-03-04 トランジェーヌTransgene ポックスウイルス腫瘍細胞崩壊性ベクター
CA2953072C (en) 2014-07-17 2021-06-29 Western Michigan University Research Foundation Composition for treating cancerous cells and a method therefor
AU2016229408A1 (en) 2015-02-25 2017-09-14 Memorial Sloan-Kettering Cancer Center Use of inactivated nonreplicating modified vaccinia virus ankara (mva) as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
EP3283088A4 (en) 2015-04-17 2018-10-24 Memorial Sloan-Kettering Cancer Center Use of mva or mvadeltae3l as immunotherapeutic agents against solid tumors
AU2017222686B2 (en) 2016-02-25 2021-12-23 Memorial Sloan Kettering Cancer Center Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapy
US10736962B2 (en) 2016-02-25 2020-08-11 Memorial Sloan Kettering Cancer Center Recombinant MVA or MVADELE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumors
EP3621646A4 (en) 2017-05-12 2021-06-02 Memorial Sloan Kettering Cancer Center VACCINIA VIRUS MUTANTS FOR CANCER IMMUNOTHERAPY
EP3703723A4 (en) 2017-10-31 2021-12-15 KaliVir Immunotherapeutics, Inc. ONCOLYTIC PLATFORM VECTOR FOR SYSTEMS ADMINISTRATION
KR20200116086A (ko) 2018-01-26 2020-10-08 유니버시티 오브 피츠버그 - 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 종양 치료를 개선하기 위한 종양 미세환경에서 대사 조절인자의 발현
CN108066370A (zh) * 2018-02-11 2018-05-25 佛山科学技术学院 一种羊传染性脓疱病毒在制备抗结直肠癌细胞药物中的应用
ES2976989T3 (es) * 2018-02-28 2024-08-14 Bionoxx Inc Composición farmacéutica para prevenir o tratar el cáncer que comprende virus antineoplásicos e hidroxicarbamida como componentes eficaces
TW202014200A (zh) * 2018-05-02 2020-04-16 賽斯 雷德曼 包含合成嵌合牛痘病毒之幹細胞及其使用方法
CA3150829A1 (en) * 2019-08-26 2021-03-04 Bionoxx Inc. Pharmaceutical composition comprising vaccinia virus and hydroxyurea as active ingredient for treatment of cancer
EP4023232A4 (en) * 2019-08-26 2022-11-30 Bionoxx Inc. PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CANCER WITH ANTI-CANCER VIRUS, IMMUNE CHECKPOINT INHIBITOR AND HYDROXYUREA AS ACTIVE INGREDIENTS
US20220288143A1 (en) * 2019-08-29 2022-09-15 Bionoxx Inc. Pharmaceutical composition for treating cancer, comprising vaccinia virus and granulopoiesis inhibitor as active ingredients
TW202305125A (zh) 2021-04-30 2023-02-01 美商凱立凡爾免疫治療股份有限公司 用於經修飾mhc表現之溶瘤病毒
WO2024038175A1 (en) * 2022-08-18 2024-02-22 Transgene Chimeric poxviruses

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6139834A (en) * 1994-06-23 2000-10-31 Georgetown University Replication-competent Herpes simplex virus mediates destruction of neplastic cells
WO2003085090A2 (en) 2002-03-29 2003-10-16 Yun Yen A human ribonucleotide reductase m2 subunit
PL2212345T3 (pl) 2007-11-19 2016-07-29 Transgene Sa Onkolityczne wektory pokswirusowe

Also Published As

Publication number Publication date
US20120114612A1 (en) 2012-05-10
US9370550B2 (en) 2016-06-21
CA2709292A1 (en) 2011-01-10
EP2451945A1 (en) 2012-05-16
CA2767561A1 (en) 2011-01-13
US20140234257A1 (en) 2014-08-21
WO2011003194A1 (en) 2011-01-13
ES2626657T3 (es) 2017-07-25
US8679509B2 (en) 2014-03-25
EP2451945A4 (en) 2013-04-03
EP2451945B1 (en) 2017-04-19
DK2451945T3 (en) 2017-07-24
PT2451945T (pt) 2017-06-14
CA2767561C (en) 2021-09-21

Similar Documents

Publication Publication Date Title
PT2451945T (pt) Vírus oncolíticos e métodos para tratar distúrbios neoplásicos
HK1255283A1 (zh) 用於治療流感的化合物和方法
HRP20180882T1 (hr) Sredstva za i postupci liječenja dlbcl
HK1201145A1 (en) Methods and devices for treating hypertension
GB2477422B (en) Apparatus and process for treating waste
EP2462507A4 (en) METHOD AND DEVICE FOR USER-REPORTABLE SAFE PATHS IN THE PRESENCE OF MALWARE
EP2323681A4 (en) METHODS OF TREATING VIRAL CONDITIONS
ZA201202976B (en) Catalystic cracking apparatus and process thereof
EP2417620A4 (en) METHOD AND DEVICE FOR TREATING OUTFLUENCES
HK1179823A1 (en) Methods for treating methotrexate-resistant disorders with 10-propargyl-10- deazaaminopterin 10--10-
GB2464356B (en) Leaf blower-vacuum apparatus with nestable blower pipe and detachable wheel
EP2323579A4 (en) METHODS AND DEVICES FOR TREATING PRESBYOPIA
PT2627818T (pt) Método e disposição para tratamento de pasta
EP2507398A4 (en) METHOD FOR PREDICTING AND TREATING STERILE INFLAMMATION AND FOR DISTINCTION BETWEEN STERILES AND INFECTIOUS INFLAMMATION
ZA201207226B (en) Compositions and methods for treating viral diseases
EP2790768A4 (en) DEVICE AND METHOD FOR THE TREATMENT OF PULMONARY HYPERTONIA
EP2403496A4 (en) COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER AND VIRAL INFECTIONS